Calgary's Foothills Medical Centre hepatology programme and South Health Campus manage Alberta's Hepatitis C patients from across the southern half of the province. Calgary's large South Asian community — including immigrants from Pakistan, India, and Afghanistan where HCV prevalence is elevated — creates substantial Hepatitis C treatment demand. Resof L provides Calgary patients with affordable Ledipasvir+Sofosbuvir cure at dramatically reduced cost versus brand Harvoni pricing.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
❓ FAQ 1: What is the difference between Resof L (Ledipasvir+Sofosbuvir) and Sofosbuvir+Velpatasvir for HCV treatment in Calgary?
Resof L (Ledipasvir+Sofosbuvir, brand Harvoni) is most effective for Genotypes 1, 4, 5, and 6. Sofosbuvir+Velpatasvir (brand Epclusa) is a pangenotypic regimen — effective across all HCV genotypes including 2 and 3. Calgary's hepatologists always confirm HCV genotype before selecting treatment — the genotyping blood test takes 1-2 weeks. Genotype 1 (most common in Calgary's European-background population, approximately 60% of Canadian HCV cases) responds excellently to Resof L with 12 weeks of treatment and SVR12 rates above 95%. Genotypes 2 and 3 (more common in Calgary's South Asian community) are better treated with Sofosbuvir+Velpatasvir. Patients with cirrhosis may require ribavirin addition or extended treatment duration regardless of genotype.
❓ FAQ 2: How is HCV transmission occurring in Calgary's South Asian community and what prevention applies?
In Calgary's South Asian community, HCV transmission patterns differ from the injection drug use route predominant in the general Canadian population. Key transmission routes in this community include: unsterile medical and dental procedures in countries of origin (where HCV prevalence is high and infection control standards historically variable), contaminated blood transfusions received before comprehensive HCV screening in South Asian countries, unsterile traditional medical practices including Hijama (cupping), traditional barbers sharing razors, and within-family transmission through shared personal care items like razors or nail clippers with an infected family member. Understanding these community-specific transmission routes helps Calgary hepatologists provide culturally appropriate counselling alongside Resof L treatment.
❓ FAQ 3: What happens to liver enzymes (ALT/AST) during and after Resof L treatment?
ALT and AST — liver inflammation markers — typically improve progressively during Resof L treatment as HCV viral replication is suppressed and liver inflammation resolves. Most patients see ALT normalise within the first 4 weeks of treatment as the virus is rapidly suppressed. After achieving SVR12 (cure), liver enzymes continue to improve in most patients — returning to normal range in those without advanced fibrosis, and improving significantly (though potentially not fully normalising) in those with cirrhosis due to residual scar tissue. A small proportion of patients experience a transient ALT flare during early treatment — a recognised phenomenon thought to reflect immune reconstitution as the immune system recovers from viral-induced suppression. Calgary hepatologists check ALT and AST at baseline, during treatment if clinically indicated, and at the post-treatment SVR12 assessment appointment.
❓ FAQ 4: How does alcohol consumption affect Resof L treatment outcomes in Calgary HCV patients?
Alcohol does not directly interact with Ledipasvir or Sofosbuvir pharmacologically — there is no dangerous drug-alcohol interaction. However, alcohol is independently hepatotoxic — it causes liver inflammation and damage through a completely separate pathway from HCV. Continued heavy alcohol use during Resof L treatment means the liver is being simultaneously repaired (HCV cure) and damaged (alcohol toxicity), reducing the net liver recovery benefit of treatment. After achieving SVR12, continued alcohol use dramatically increases the risk of progression to cirrhosis and hepatocellular carcinoma — even after HCV is cured, alcohol-related liver disease can independently progress to end-stage liver failure. Calgary hepatologists discuss alcohol reduction or cessation as part of every HCV treatment conversation, and connect patients with addiction services where needed.
❓ FAQ 5: Can HCV be cured with Resof L in patients who are also HIV-positive (HIV/HCV co-infection)?
Yes — HIV/HCV co-infected patients can be cured of HCV with Ledipasvir+Sofosbuvir (Resof L) with SVR12 rates comparable to HCV-monoinfected patients. The ION-4 trial specifically studied Resof L in HIV/HCV co-infected patients on ARTs and demonstrated 96% SVR12 — equivalent to monoinfected patients. Key considerations for Calgary co-infected patients: drug interactions between Resof L and antiretroviral regimens must be checked carefully — Tenofovir-containing ARTs combined with Ledipasvir can increase Tenofovir exposure by 40%, requiring renal monitoring; some older ARTs like Efavirenz reduce Ledipasvir levels and may require regimen modification. Calgary's HIV and hepatology specialists collaborate closely for co-infected patients, often holding joint clinic appointments to manage both conditions simultaneously.
